Arthritis

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, MRI, INN, Risk, Contraindication, AZA, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Contraindication, AZA, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Psoriasis, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, Pemphigus, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, C-reactive protein, MRI, INN, Risk, Polyarthritis, Lung, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Bacteria, Anatomy, IIA, Skin, DSM-IV codes, ATC, Joint, Pain, Psoriatic arthritis, Itch, Bleeding, Disease, Ageing, Nonsteroidal anti-inflammatory drug, Human, Safety, CRP, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Patient, Medical Subject Headings, International, Arthritis, Language, Blood, Select, Juvenile idiopathic arthritis, Methotrexate, Common, TNF, PUVA, Swelling, European Medicines Agency, Spine, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Nepexto, etanercept, Date of authorisation: 20/05/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04

Retrieved on: 
Wednesday, December 13, 2023
University of Leeds, Pfizer, Pain management, Pain, Arthritis, NGF, Knee, School, Osteoarthritis, University, Biomarker, CSO, Cartilage, Safety, Pharmaceutical industry

The multiple-arm, multicentre, prospective, randomized, double-blind, placebo-controlled Phase II study enrolled more than 500 participants with pain due to osteoarthritis of the knee ( ClinicalTrials.gov ID: NCT05618782 ).

Key Points: 
  • The multiple-arm, multicentre, prospective, randomized, double-blind, placebo-controlled Phase II study enrolled more than 500 participants with pain due to osteoarthritis of the knee ( ClinicalTrials.gov ID: NCT05618782 ).
  • The trial was designed to evaluate the efficacy, safety and tolerability of five, monthly, infusions of LEVI-04 as compared to placebo in participants with radiographic and symptomatic knee osteoarthritis.
  • It operates across four receptor pathways in the neurotrophin system and is designed to supplement the existing endogenous p75NTR binding protein and returning normal neurotrophin function.
  • While the potential of the neurotrophin pathway to provide effective pain relief is recognised, safety issues have significantly hampered development.

United States Walk-in Bathtubs Market Outlook Report 2023-2028, Featuring Key Vendors Kohler, LIXIL, Investindustrial, SWCORP, ARIEL & Ella's Bubbles - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 28, 2023
Construction & Property, Interior Design, DSM-IV codes, LED, ARIEL, Internet of things, BOCA, Traction, Lighting, Relaxation, Arthritis, Management

This report offers market size & forecast data for the walk-in bathtubs market in the US.

Key Points: 
  • This report offers market size & forecast data for the walk-in bathtubs market in the US.
  • This report provides a comprehensive and current market scenario of the US walk-in bathtubs, including the US walk-in bathtubs market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present walk-in bathtubs market and its market dynamics for 2023-2028 in the US.
  • In the combo segment of the walk-in bathtubs market, people prefer to buy grab handles, anti-slip surface coatings, and LED lighting.

Peachtree Group Appoints Sameer Nair as Senior Vice President of Equity Asset Management

Retrieved on: 
Tuesday, December 19, 2023
Commercial Building & Real Estate, Construction & Property, REIT, Arthritis, Multimedia, Urban Land Institute, Acquisition, Cornell University, Investment, Growth, Arthritis Foundation, Financial services

Peachtree Group, a diversified commercial real estate investment firm, has named Sameer Nair as senior vice president of equity asset management.

Key Points: 
  • Peachtree Group, a diversified commercial real estate investment firm, has named Sameer Nair as senior vice president of equity asset management.
  • In this role, he will oversee and implement asset oversight to Peachtree’s real estate portfolio and preferred equity investments.
  • View the full release here: https://www.businesswire.com/news/home/20231219362690/en/
    Peachtree Group, a diversified commercial real estate investment firm, has named Sameer Nair (pictured) as senior vice president of equity asset management.
  • (Photo: Business Wire)
    As an experienced asset manager with development and transactional experience, Nair brings unique experiences and capabilities to the firm.

Pioneers of PEMF Technology Launch RollnRest's Customizable Build-A-Dog-Bed System

Retrieved on: 
Friday, December 22, 2023
PEMF, Pet, Dog, Mix, Electromagnetic field, Bed, Arthritis, Sleep, Life

The introduction of Petspemf Pad garnered attention as several pet owners shared testimonials about its efficacy in managing joint issues and arthritis.

Key Points: 
  • The introduction of Petspemf Pad garnered attention as several pet owners shared testimonials about its efficacy in managing joint issues and arthritis.
  • After meticulous research and years of development, RollnRest is happy to unveil an entirely new approach to dog beds — the RollnRest Customizable Build-A-Dog-Bed System.
  • Investing in a quality dog bed is not just about aesthetics; it's a proactive measure to enhance a pet's overall well-being.
  • RollnRest invites pet owners to consider the importance of a dog bed that aligns with their dog's unique needs and preferences.

The Inner Circle Acknowledges, Haris Choudry as a Distinguished Healthcare Provider for his contributions to the fields of Physiatry and Orthopedics

Retrieved on: 
Tuesday, December 19, 2023
PM&R, Mentorship, Quality of life, Hospital, Inner circle, Public, Tendon, SUNY Downstate Medical Center, Joint, Medical director, Chronic pain, Spinal cord, Brain, Health, MD, Bachelor, Physical medicine and rehabilitation, Education, Disability, University, International Society, Knowledge, Ligament, Amputation, PM, Clinical, Medicine, Public health, Arthritis

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Haris Choudry is acknowledged as a Distinguished Healthcare Provider for his contributions to the fields of Physiatry and Orthopedics.

Key Points: 
  • NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Haris Choudry is acknowledged as a Distinguished Healthcare Provider for his contributions to the fields of Physiatry and Orthopedics.
  • Dr. Choudry pursued higher education at the University of Oklahoma where he earned a Bachelor's degree in Biochemistry.
  • He then continued at the University of Oklahoma College of Medicine where he received his medical degree and completed his residency in physical medicine & rehabilitation at SUNY Downstate Health Sciences University.
  • Physiatrists treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles, and tendons.